FDA Drug Withdrawal Rate In Post-User Fee Era Higher Than Pre-PDUFA
Executive Summary
The rate of drug withdrawals due to safety concerns since FDA started collecting user fees has crept past the pre-user fee rate, the Center for Drug Evaluation & Research says in its "FDL-12004 Report to the Nation.
You may also be interested in...
Drug Withdrawals Due To Safety Unrelated To Approval Speed – Tufts Study
A study from the Tufts Center for the Study of Drug Development concludes that the speed of FDA's review of a product does not correlate with whether it will be withdrawn
Drug Withdrawals Due To Safety Unrelated To Approval Speed – Tufts Study
A study from the Tufts Center for the Study of Drug Development concludes that the speed of FDA's review of a product does not correlate with whether it will be withdrawn
Purdue Withdraws Palladone; FDA Evaluating Other Extended-Release Opiates
FDA is evaluating the potential for an alcohol interaction with other sustained-release opiates following the withdrawal of Purdue Pharma's Palladone due to the potential for serious alcohol-related adverse events